Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 6.9% in July

Dyne Therapeutics, Inc. (NASDAQ:DYN) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 9,880,000 shares, an increase of 6.9% from the July 15th total of 9,240,000 shares. Based on an average trading volume of 1,260,000 shares, the days-to-cover ratio is currently 7.8 days.

Dyne Therapeutics Stock Performance

Shares of DYN stock traded up $0.73 during trading on Monday, hitting $46.12. The company had a trading volume of 1,575,080 shares, compared to its average volume of 1,578,634. The firm has a market capitalization of $4.03 billion, a P/E ratio of -11.62 and a beta of 1.07. The stock’s 50-day moving average price is $39.20 and its 200 day moving average price is $31.15. Dyne Therapeutics has a one year low of $6.40 and a one year high of $46.74.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, research analysts anticipate that Dyne Therapeutics will post -3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. StockNews.com raised Dyne Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Oppenheimer reaffirmed an “outperform” rating and issued a $47.00 target price on shares of Dyne Therapeutics in a research report on Monday, May 6th. Chardan Capital upped their target price on Dyne Therapeutics from $31.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, May 21st. Piper Sandler upped their target price on Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Finally, Guggenheim upped their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $50.60.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, COO Susanna Gatti High sold 29,787 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $35.01, for a total transaction of $1,042,842.87. Following the transaction, the chief operating officer now owns 148,792 shares of the company’s stock, valued at $5,209,207.92. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,590 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $30.23, for a total transaction of $48,065.70. Following the transaction, the senior vice president now owns 115,105 shares of the company’s stock, valued at $3,479,624.15. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Susanna Gatti High sold 29,787 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $35.01, for a total value of $1,042,842.87. Following the transaction, the chief operating officer now directly owns 148,792 shares in the company, valued at approximately $5,209,207.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 163,676 shares of company stock valued at $5,270,510. 20.77% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DYN. RA Capital Management L.P. bought a new stake in Dyne Therapeutics during the first quarter worth $140,666,000. Janus Henderson Group PLC lifted its stake in Dyne Therapeutics by 23,512.0% during the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after purchasing an additional 2,663,910 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Dyne Therapeutics during the fourth quarter worth $15,758,000. Price T Rowe Associates Inc. MD lifted its stake in Dyne Therapeutics by 8,284.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after purchasing an additional 1,118,590 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Dyne Therapeutics by 47.7% during the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after purchasing an additional 1,110,629 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.